These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 793522)

  • 21. Studies on immunity to toxins of Clostridium botulinum. VI. Purification and detoxification of type D toxin and the immunological response to toxoid.
    CARDELLA MA; DUFF JT; WINGFIELD BH; GOTTFRIED C
    J Bacteriol; 1960 Mar; 79(3):372-8. PubMed ID: 13807649
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical Study of New Tetravalent (Type A, B, E, and F) Botulinum Toxoid Vaccine Derived from M Toxin in Japan.
    Torii Y; Sugimoto N; Kohda T; Kozaki S; Morokuma K; Horikawa Y; Ginnaga A; Yamamoto A; Takahashi M
    Jpn J Infect Dis; 2017 Jul; 70(4):423-429. PubMed ID: 28250257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.
    Held DM; Shurtleff AC; Fields S; Green C; Fong J; Jones RG; Sesardic D; Buelow R; Burke RL
    Clin Vaccine Immunol; 2010 Jun; 17(6):930-6. PubMed ID: 20410329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulism among penned pheasants and protection by vaccination with C1 toxoid.
    Kurazono H; Shimozawa K; Sakaguchi G; Takahashi M; Shimizu T; Kondo H
    Res Vet Sci; 1985 Jan; 38(1):104-8. PubMed ID: 3883454
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a purified cholera toxoid. II. Preparation of a stable, antigenic toxoid by reaction of purified toxin with glutaraldehyde.
    Rappaport RS; Bonde G; McCann T; Rubin BA; Tint H
    Infect Immun; 1974 Feb; 9(2):304-17. PubMed ID: 4205946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The protective effect of Clostridium novyi type B alpha-toxoid against challenge with spores in guinea pigs.
    Amimoto K; Sasaki O; Isogai M; Kitajima T; Oishi E; Okada N; Yasuhara H
    J Vet Med Sci; 1998 Jun; 60(6):681-5. PubMed ID: 9673937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Purification of Clostridium botuliunum type F progenitor toxin.
    Oishi I; Sakaguchi G
    Appl Microbiol; 1974 Dec; 28(6):923-8. PubMed ID: 4615636
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunogenic properties of type E botulinum toxoid].
    Switalska A; Trembowler P; Meisel H
    Med Dosw Mikrobiol; 1965; 17(4):305-11. PubMed ID: 5326421
    [No Abstract]   [Full Text] [Related]  

  • 29. Immunogenicity of Clostridium septicum in guinea pigs.
    Claus KD; Kolbe DR
    Am J Vet Res; 1979 Dec; 40(12):1752-6. PubMed ID: 525895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An improved method for development of toxoid vaccines and antitoxins.
    Jones RG; Liu Y; Rigsby P; Sesardic D
    J Immunol Methods; 2008 Aug; 337(1):42-8. PubMed ID: 18571196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [STUDY OF BOTULINUM TOXOIDS. VI. TYPE D BOTULINUM TOXOID].
    VOROBEV AA; VASILEV NN; SHEVELEV VM; VORONOVA ZA; PETROVA EK; BAZHENOVA GA; ANDROSHCHUK SM
    Zh Mikrobiol Epidemiol Immunobiol; 1963 Sep; 40():87-92. PubMed ID: 14119975
    [No Abstract]   [Full Text] [Related]  

  • 32. Cultural and physiological characteristics of Clostridium botulinum type G and the susceptibility of certain animals to its toxin.
    Ciccarelli AS; Whaley DN; McCroskey LM; Gimenez DF; Dowell VR; Hatheway CL
    Appl Environ Microbiol; 1977 Dec; 34(6):843-8. PubMed ID: 74236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serological studies of types A, B, and E botulinal toxins by passive hemagglutination and bentonite flocculation.
    Johnson HM; Brenner K; Angelotti R; Hall HE
    J Bacteriol; 1966 Mar; 91(3):967-74. PubMed ID: 5326104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of toxigenic Clostridium botulinum type E by enzyme immunoassay.
    Dezfulian M; Bartlett JG
    Diagn Microbiol Infect Dis; 1991; 14(1):11-5. PubMed ID: 2013205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clostridium botulinum type E toxin and toxoid.
    BARRON AL; REED GB
    Can J Microbiol; 1954 Oct; 1(2):108-17. PubMed ID: 14352045
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparative study on the immunogenic properties of Clostridium perfringens type A toxoid.
    Shemanova GF; Vlasova EV; Dmitrieva LN; Trapezov EV; Gorbacheva LD
    J Hyg Epidemiol Microbiol Immunol; 1986; 30(3):323-9. PubMed ID: 2877025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of purified Habu snake-venom toxoid in guinea pigs and monkeys with special reference to HR1 component.
    Sadahiro S; Omori-Satoh T; Yamauchi K; Kondo S; Ishida S; Murata R
    Jpn J Med Sci Biol; 1981 Aug; 34(4):213-30. PubMed ID: 6798252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basis of type A and F toxicities of Clostridium botulinum strain 84.
    Sugiyama H; Mizutani K; Yang KH
    Proc Soc Exp Biol Med; 1972 Dec; 141(3):1063-7. PubMed ID: 4566748
    [No Abstract]   [Full Text] [Related]  

  • 39. Atypical toxin variant of Clostridium botulinum type B associated with infant botulism.
    Hatheway CL; McCroskey LM; Lombard GL; Dowell VR
    J Clin Microbiol; 1981 Dec; 14(6):607-11. PubMed ID: 7037830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Studies on immunity to toxins of Clostridium botulinum. II. Production and purification of type B toxin for toxoid.
    DUFF JT; KLERER J; BIBLER RH; MOORE DE; GOTTFRIED C; WRIGHT GG
    J Bacteriol; 1957 May; 73(5):597-601. PubMed ID: 13428702
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.